These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 26159859)

  • 21. Advances for the treatment of primary central nervous system lymphoma (review).
    Yamanaka R; Tanaka R
    Oncol Rep; 2004 Sep; 12(3):563-8. PubMed ID: 15289838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for central nervous system lymphomas in immunocompetent patients.
    Jahnke K; Thiel E
    Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recent advances in the treatment of primary central nervous system lymphoma].
    Nakamaki T
    Brain Nerve; 2014 Aug; 66(8):969-79. PubMed ID: 25082318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Present and future treatment options for primary CNS lymphoma.
    Citterio G; Reni M; Ferreri AJ
    Expert Opin Pharmacother; 2015; 16(17):2569-79. PubMed ID: 26371872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
    Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
    Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
    Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
    Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
    Chihara D; Fowler NH; Oki Y; Fanale MA; Fayad LE; Westin JR; Hagemeister FB
    Br J Haematol; 2017 Dec; 179(5):851-854. PubMed ID: 27502933
    [No Abstract]   [Full Text] [Related]  

  • 29. Comment: defining cure in primary CNS lymphoma.
    Batchelor TT
    Neurology; 2014 Apr; 82(15):1373. PubMed ID: 24634452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis and management of primary CNS lymphoma.
    Roth P; Korfel A; Martus P; Weller M
    Expert Rev Anticancer Ther; 2012 May; 12(5):623-33. PubMed ID: 22594897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
    Ferreri AJ; Blay JY; Reni M; Pasini F; Spina M; Ambrosetti A; Calderoni A; Rossi A; Vavassori V; Conconi A; Devizzi L; Berger F; Ponzoni M; Borisch B; Tinguely M; Cerati M; Milani M; Orvieto E; Sanchez J; Chevreau C; Dell'Oro S; Zucca E; Cavalli F
    J Clin Oncol; 2003 Jan; 21(2):266-72. PubMed ID: 12525518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
    Kuitunen H; Tokola S; Siniluoto T; Isokangas M; Sonkajärvi E; Alahuhta S; Turpeenniemi-Hujanen T; Jantunen E; Nousiainen T; Vasala K; Kuittinen O
    J Neurooncol; 2017 Jan; 131(2):293-300. PubMed ID: 27752883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
    Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
    Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of patients with primary central nervous system lymphoma treated outside clinical trials.
    Hart A; Baars JW; Kersten MJ; Brandsma D; van Tinteren H; de Jong D; Spiering M; Dewit L; Boogerd W
    Neth J Med; 2014 May; 72(4):218-23. PubMed ID: 24829178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances and challenges in the treatment of primary central nervous system lymphoma.
    Yang H; Xun Y; Yang A; Liu F; You H
    J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary Central Nervous System Lymphoma in an Immunocompetent Young Adult Patient: A Rare Case.
    Wirdah A; Djamaludin N; Syahrir M; Andayani YD; Andriani M; Diansari Y
    Acta Med Indones; 2023 Jan; 55(1):107-109. PubMed ID: 36999259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Our experience with the treatment of primary lymphomas of the central nervous system].
    Motyčková M; Smolej L; Belada D; Malý J; Zák P
    Vnitr Lek; 2012 Dec; 58(12):915-21. PubMed ID: 23427949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine.
    Sieg N; Naendrup JH; Gödel P; Balke-Want H; Simon F; Deckert M; Gillessen S; Kreissl S; Bröckelmann PJ; Borchmann P; von Tresckow B; Heger JM
    Eur J Haematol; 2021 Aug; 107(2):202-210. PubMed ID: 33960535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of primary central nervous system lymphoma in the immunocompetent patient].
    Sierra Del Rio M; Benouaich-Amiel A; Psimaras D; Dehais C; Hoang-Xuan K
    Rev Neurol (Paris); 2008; 164(6-7):569-74. PubMed ID: 18565356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary CNS lymphoma.
    Gerstner E; Batchelor T
    Expert Rev Anticancer Ther; 2007 May; 7(5):689-700. PubMed ID: 17492932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.